Innovative Approach for Enhancing Testing of HIV, Hepatitis B, and Hepatitis C in the General Population: Protocol for an Acceptability and Feasibility Study (BaroTest 2016)

Abstract

BackgroundDespite substantial screening for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) infections in France, a great number of infected persons remain undiagnosed. In this context, Santé publique France experimented with a new screening approach for HBV, HCV, and HIV infection, based on home self-sampling using dried blood spot (DBS) for blood collection.ObjectiveThe objectives of the BaroTest study were to assess the acceptability and feasibility of this approach and to update the prevalence estimates of HBV, HCV, and HIV infections in the general population.MethodsParticipants were enrolled using the 2016 Health Barometer, a national cross-sectional telephone survey based on a large representative sample of the general population aged 15 to 75 years (N=15,000). Upon completion of the questionnaire, any participant in the Health Barometer aged 18 to 75 years, having medical health insurance, and not under guardianship was invited to receive a self-sampling kit delivered by standard postal mail and to return the DBS card to the laboratory. The laboratory was then responsible for reporting the results to the participants. Acceptability of the protocol was based on the percentage of eligible individuals agreeing to receive the self-sampling kit, on the proportion of people returning the DBS card, and on the proportion of participants out of the total eligible population. The feasibility of the approach was based on the number of participants with adequately filled blood spots and the number of participants with blood spots for which at least one virological analysis could be performed. A complex system of reminders was implemented to increase the participation rate. Accordingly, we assumed that 35.00% (4900/14,000) of eligible persons would accept and return their DBS card. As the highest expected prevalence was for HBV infection, estimated at 0.65% in 2004, 5000 persons would make it possible to estimate this prevalence with an accuracy of approximately 0.22%. All indicators can be analyzed according to the characteristics of the participants collected in the Health Barometer questionnaire. BaroTest was approved by the French Ethics Committee (November 11, 2015) and the Commission on Information Technology and Liberties (December 24, 2015). The study has been registered by the French medical authority under number 2015-A01252-47 on November 10, 2015.ResultsThe results on acceptability and feasibility are expected in the last quarter of 2018 and those on the prevalence estimates in the first semester of 2019.ConclusionsThe BaroTest results will help to inform new strategies for HIV, HBV, and HCV screening, and the Health Barometer provides a reliable updated assessment of the burden of HBV, HCV, and HIV infections in the general population in France while reducing the costs typically associated with this type of research.Registered Report IdentifierRR1-10.2196/9797

Research in the Time of Coronavirus: Continuing Ongoing Studies in the Midst of the COVID-19 Pandemic

“…Some labs provide infectious disease testing services which can examine 4th generation HIV antibody testing using dried blood spot and chlamydia and gonorrhea testing using mail-in swabs, as well as mail-in samples for Hepatitis B and C testing [31][32][33]. Alcohol use can be remotely monitored using Bluetooth-enabled breathalyzers that estimate breath alcohol concentration or wrist-worn alcohol biosensors that continuously measure transdermal alcohol content [34][35][36].…”

HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy

“…To our knowledge, BaroTest is the first survey on HCV, HBV and HIV screening based on home-based blood self-sampling among the general population. A comprehensive system of reminders was put in place to prompt those who had agreed to participate to carry out the home-sampling (Figure 1 supplementary material) (22). Of all those initially invited to participate in the survey, almost 40% returned DBS, demonstrating that home-based blood self-sampling may constitute an effective and inexpensive tool in epidemiological studies.…”

French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long

“…BaroTest used home-based blood self-sampling on dried blood spots (DBS). From these DBS, detection of HCV antibodies and HCV RNA (in case of anti-HCVpositive samples) was performed [24,25].…”